139 related articles for article (PubMed ID: 10076539)
1. Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells.
Etore F; Tenu JP; Teiger E; Adnot S; Lonchampt MO; Pirotzki E; Le Doan T
Biochem Pharmacol; 1998 May; 55(9):1465-73. PubMed ID: 10076539
[TBL] [Abstract][Full Text] [Related]
2. Use of a simple fractionation method to evaluate binding, internalization and intracellular distribution of oligonucleotides in vascular smooth muscle cells.
Eboue D; Auger R; Angiari C; Le Doan T; Tenu JP
Arch Physiol Biochem; 2003 Jul; 111(3):265-72. PubMed ID: 14972750
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior.
Shoeman RL; Hartig R; Huang Y; Grüb S; Traub P
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):291-308. PubMed ID: 9303181
[TBL] [Abstract][Full Text] [Related]
4. [A simple method for the study of cytosolic content of oligonucleotides in cells].
Tenu JP; Etoré F; Le Doan T
C R Acad Sci III; 1997 Jun; 320(6):477-86. PubMed ID: 9247027
[TBL] [Abstract][Full Text] [Related]
5. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries.
Farrell CL; Bready JV; Kaufman SA; Qian YX; Burgess TL
Antisense Res Dev; 1995; 5(3):175-83. PubMed ID: 8785473
[TBL] [Abstract][Full Text] [Related]
6. Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor.
Robinson CJ; Scott PH; Allan AB; Jess T; Gould GW; Plevin R
Biochem J; 1996 Nov; 320 ( Pt 1)(Pt 1):123-7. PubMed ID: 8947476
[TBL] [Abstract][Full Text] [Related]
7. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
Hu Q; Bally MB; Madden TD
Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
[TBL] [Abstract][Full Text] [Related]
8. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
9. Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide.
Herbert JM; Guy AF; Lamarche I; Mares AM; Savi P; Dol F
J Cell Physiol; 1997 Feb; 170(2):106-14. PubMed ID: 9009139
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell growth.
Aoki M; Morishita R; Matsushita H; Hayashi S; Nakagami H; Yamamoto K; Moriguchi A; Kaneda Y; Higaki J; Ogihara T
Hypertension; 1999 Aug; 34(2):192-200. PubMed ID: 10454440
[TBL] [Abstract][Full Text] [Related]
11. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide.
Pichon C; Freulon I; Midoux P; Mayer R; Monsigny M; Roche AC
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):335-43. PubMed ID: 9303185
[TBL] [Abstract][Full Text] [Related]
12. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
J Clin Invest; 1994 Apr; 93(4):1458-64. PubMed ID: 8163650
[TBL] [Abstract][Full Text] [Related]
13. Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences.
Chaikof EL; Caban R; Yan CN; Rao GN; Runge MS
J Biol Chem; 1995 Mar; 270(13):7431-6. PubMed ID: 7706289
[TBL] [Abstract][Full Text] [Related]
14. Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent.
Santiago FS; Atkins DG; Khachigian LM
Am J Pathol; 1999 Sep; 155(3):897-905. PubMed ID: 10487847
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of antisense analogues in the central nervous system.
Szklarczyk A; Kaczmarek L
Neurochem Int; 1997 Sep; 31(3):413-23. PubMed ID: 9246683
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide biological activity: relationship to the cell cycle and nuclear transport.
Wu-Pong S; Bard J; Huffman J; Jimerson J
Biol Cell; 1997 Jul; 89(4):257-61. PubMed ID: 9447700
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
20. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
